Biotech startup Virometix obtains CHF 7.5 M in a series B round


Virometix is developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases. The company has raised CHF 7.5 million Series B equity financing round bringing the company’s total funding to CHF 17.8 million.



Virometix AG is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. In an increasingly global world, there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases, including cancer. Rational molecular design, chemical synthesis and Virometix' proprietary “Synthetic Virus-Like Particle” platform technology allow for the rapid production and optimization of vaccine candidates with the potential to demonstrate superior properties in terms of safety, efficacy and stability.

The Series B round included participation from existing and new private investors. They will be added to the previous seed and Series A financings of CHF 10.3 million, bringing the total capital raised to date by Virometix to CHF 17.8 million.

The funds will ensure the company can complete phase 1 clinical trial of its lead asset V-306 in RSV (respiratory syncytial virus), advance preclinical development of its vaccine candidates against SARS-CoV-2, progress other research collaborations and strengthen the team.

Anna Sumeray, Chief Executive Officer of Virometix, commented: “We are delighted with the continued support and confidence from our existing investors and very happy to have attracted interest from new investors. We are excited about the differentiation of our platform and look forward to generating positive data over the coming months.”

New board members
In line with the funding, the company appointed Axel Polack and Anna Sumeray to the board of directors. Polack holds a Medical Doctorate degree from the Albert-Ludwigs-Universität Freiburg and Habilitation (postdoctoral lecture qualification) in Virology from the Ludwig-Maximilians-Universität Munich. He is a member on various boards and a biotech investor and was a partner at TVM Capital from 2000 until 2014.

Sumeray is the CEO of Virometix and has more than has over 25 years of experience in the life sciences sector. She has a combination of strategic consultancy, hands-on P&L leadership and deal transaction experience in big pharmaceutical and small biotechnology companies, globally, across Europe and within individual countries.

(Press release)
Photo: Axel Polack and Anna Sumeray (CEO)